0611/26SCR019-18/R6RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
5
Continued ➔
Media Outlet Date Article / Coverage
eCancer 5/30/26 ASCO 2026: Combining Targeted Immunotherapies
With Standard R-Chop Delays Progression of Aggressive
B-Cell Lymphomas
Endpoints 5/28/26 After Leaving Legend, Founding Scientist Frank Fan Is Ready
to Showcase His Next Project
Endpoints 6/1/26 ASCO in Brief: Lilly's Plenaries; Incyte's Frontline Data
in Lymphoma
Fierce Pharma 5/30/26 ASCO: With Bispecifics on Its Heels, Incyte Positions Monjuvi
Combo for First-Line DLBCL
Healio 5/30/26 Regimen Confers 'Meaningful' Benefit in Aggressive
Lymphoma, May Become a New Standard
MedPage Today 5/30/26 Frontline Targeted Therapies Plus R-CHOP Boosts PFS in
High-Risk B-Cell Lymphomas
Medscape 5/30/26 Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL
Oncology News
Central
5/30/26 ASCO 2026: First Featured Studies Introduce Potential
New Standards
Rare Disease Advisor 6/1/26 Tafasitamab Combination Regimen Bests R-CHOP Alone in
High-Risk DLBCL
The ASCO Post 6/2/26 Combining Targeted Immunotherapies With Standard
R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
The ASCO Post 6/11/26 Tafasitamab/Lenalidomide Combination vs R-CHOP in High-
Risk DLBCL: Phase III frontMIND Trial
Krish Patel, MD
SCRI
Media Outlet Date Article / Coverage
Healio 6/3/26 'This Matters': Hem/onc Fellows Embrace AI but Lack
Formal Training to Guide Its Use
Debra Patt, MD, PhD, MBA
SCRI a Texas Oncology I The US Oncology Network
